Oxidative Stress Biomarkers in Urine of Patients with Hepatitis B and C

Abstract

Objective: The aim of our study is to determine the role of oxidative stress biomarkers in hepatic damage in hepatitis B virus (HBV) and hepatitis C virus (HCV)-infected patients. Materials and Methods: Forty-eight patients with chronic hepatitis B, 15 patients with chronic hepatitis C and 30 healthy individuals as a control group were included in this study. Serum alanine-aminotransferase (ALT) and aspartate aminotransferase (AST) levels, urine oxidative stress biomarkers such as malondialdehyde (MDA) levels, superoxide dismutase (SOD-1) and catalase (CAT) activities were measured. Results: Urine MDA levels increased in patients with HBV and HCV compared to the control group. It was higher in HCV patients than HBV patients (p<0.001). Besides, while CAT and SOD-1 activities were decreased in the urine of patients with HCV, they increased in the urine of patients with HBV compared to controls (p<0.05). Furthermore, urine CAT ve SOD-1 activities in patients with HBV were statistically significantly higher than those of the HCV patients (p<0.001). Conclusion: Increase in urine MDA levels in hepatitis forms may be valuable in monitoring in viral hepatitis cases. Also, we thought that insufficiency of antioxidant barrier in patients with HCV may cause oxidative damage, so antioxidant treatment may useful and should be added to the combined therapy for these patients. Turkish Başlık: Hepatit B VE C' li Hastalarda İdrarda Oksidatif Stres Göstergeleri Anahtar Kelimeler: İdrar, oksidatif stres, hepatit B, hepatit C, transaminazlar Amaç: Bu çalışma da, HBV ve HCV infeksiyonlu hastalarda karaciğer hasarı üzerine oksidatif stres biyomarkırlarının rolünün saptanması amaçlandı. Hastalar ve Yöntemler: Kronik hepatit B'li 48, Kronik hepatit C'li 15 hasta ve 30 sağlıklı birey kontrol grubu olarak çalışmaya alındı. Kontrol ve hasta gruplarının serumlarında alanin-aminotransferaz (ALT) ve aspartat-transferaz (AST) düzeyleri, idrarda katalaz (CAT), süperoksit dismütaz (SOD-1) aktiviteleri ve malondialdehit (MDA) düzeyleri ölçüldü. Bulgular: İdrar MDA düzeylerinin HBV ve HCV'li hastalarda kontrol grubuna göre artttığı tespit edildi. HCV'li hastalarda MDA düzeyleri HBV'li hastalara göre daha yüksekti (p<0.001). Üstelik, HCV'li hastaların idrarında CAT ve SOD-1 aktiviteleri düşük bulunurken, bu enzimlerin HBV'li hastaların idrarında yüksek olduğu gözlendi. Bununla beraber, HBV'li hastalarında idrar CAT ve SOD aktiviteleri HCV'li hastalarından düşük olduğu gözlendi.HCV'li hastalarda MDA düzeyleri HBV'li hastalara göre daha yüksekti (p<0.001). Üstelik, HCV'li hastaların idrarında CAT ve SOD-1 aktiviteleri düşük bulunurken, bu enzimlerin HBV'li hastaların idrarında yüksek olduğu gözlendi. Bununla beraber, HBV'li hastalarında idrar CAT ve SOD aktiviteleri HCV'li hastalarından düşük olduğu gözlendi. Sonuç: İdrar MDA düzeylerindeki artış viral hepatit vakalarının takibinde değerli olabilir. HBV'li hastalarda antioksidan enzim aktivitelerindeki artış oksidatif strese karşı hücresel yanıt olabilir. Bunun yanında, HCV'li hastalarında ki antioksidan bariyer yetersizliği oksidatif hasara neden olabilir, bu yüzden bu hastaların tedavisine antioksidan maddelerin eklenmesinin yararlı olabileceği düşüncesindeyiz.

Keywords

• Urine, oxidative stress, hepatitis B, hepatitis C, transaminases

Oxidative Stress Biomarkers in Urine of Patients with Hepatitis B and C

Öz

References

1. Halliwell B, Gutteridge JM, Cross CE. Free radicals, antioxi- dants, and human disease: where are we now? J Lab Clin Med 1992;119:598-620.
2. Sies H. Strategies of antioxidant defences. Eur j Biochem 1993;215:213-9. [CrossRef]
3. Larrea E, Beloqui O, Munos-Navas MA, Civeira MP, Prieto J. Su- peroxide dismutase in patients with chronic hepatitis C virus in- fection. Free Radic Biol Med 1998;24:1235-41. [CrossRef]
4. Parola M, Robino G. Oxidative stress related molecules and liver fibrosis. J Hepatol 2001;35:297-306. [CrossRef]
5. Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 2000;21:49-98. [CrossRef]
6. Broide E, Klinowski E, Koukoulis G, Hadzic N, Portmann B, Baker A, et al. Superoxide dismutase activity in children with chronic liver diseases. J Hepathol 2000;32:188-92. [CrossRef]
7. Britton RS, Bacon BR. Role of free radicals in liver diseases and hepatic fibrosis. Hepatogastroenterology 1994;41:343-8.
8. Fridovich I. Superoxide dismutase. Adv Enzymol Relat Areas Mol Biol 1974;41:35-97.

9. Beutler, E. Red Cell Metabolism. A manual of biochemical meth- ods. 2nd edition, Grune and Stratton Inc., New York; 1984.
10. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in ani- mal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8. [CrossRef]
11. Irshad M, Chaudhuri PS, Joshi YK. Superoxide dismutase and to- tal anti-oxidant levels in various forms of liver diseases. Hepatol Res 2002;23:178-84. [CrossRef]
12. De Maria N, Colantoni A, Fagiuoli S, Liu G-J, Rogers BK, Fari- nati F, et al. Association between reactive oxygen species and diseaseactivity in chronic hepatitis C. Free Radic Biol Med 1996;21:291-5. [CrossRef]
13. Paradis V, Mathurin P, Kollinger M, Imbert-Bismut F, Charlotte F, Piton A, et al. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol 1997;50:401-6. [CrossRef]
14. Boya P, de la Peña A, Beloqui O, Larrea E, Conchillo M, Castelruiz Y, et al. Antioxidant status and glutathione metabolism in periph- eral blood mononuclear cells from patients with chronic hepatitis C. J Hepatol 1999;31:808-14. [CrossRef]
15. Romero MJ, Bosch-Morell F, Romero B, Rodrigo JM, Sera MA, Romero FJ. Serum malondialdehyde: possible use for the clinical management of chronic hepatitis C patients. Free Radic Biol Med 1998;25:993-7. [CrossRef]
16. Chrobot AM, Szaflarska-Szczepanik A, Drewa G. Antioxidant de- fense in children with chronic viral hepatitis B and C. Med Sci Monit 2000;6:713-8.
17. Loginov AS, Matiushin BN, Tkachev VD. Enzyme system for dis- mutation of active forms of oxygen in the liver during chronic impairment of the hepatobiliary system. Vopr Med Khim 1991;37:31-3.
18. Cıragil P, Belge Kurutas E, Kokoglu OF, Aral M. Oxidative stress in patients with chronic hepatitis B and C. Balkan Med J 2011;28:300-3.
19. Yasuyama T, Inoue K, Kojima T, Sasaki H. Activities, electropho- reticprofiles and immunolocalization of superoxide dismutase in human liver specimens. Jpn J Med 1988;27:34-41. [CrossRef]
20. Dikici I, Mehmetoglu I, Dikici N, Bitirgen M, Kurban S. Investiga- tion of oxidative stress and some antioxidants in patients with acute and chronic viral hepatitis B and the effect of interferon- treatment. Clin Biochem 2005;38:1141-4. [CrossRef]
21. Osman HG, Gabr OM, Lotfy S, Gabr S. Serum levels of bcl-2 and cellular oxidative stress in patients with viral hepatitis. Indian J Med Microbiol 2007;25:323-9. [CrossRef]
22. Demirdag K, Yilmaz S, Ozdarendeli A, Ozden M, Kalkan A, Kilic SS. Levels of plasma malondialdehyde and erythrocyte antioxi- dant enzyme activities in patients with chronic hepatitis B. Hepa- togastroenterology 2003;50:766-70.